Arrowhead Pharmaceuticals, Inc. (ARWR) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-04
(Q3 2026)
— full calendar
Earnings Reports
-
Arrowhead Pharmaceuticals (ARWR) Q1 2026: $1.33B Capital Infusion Powers Pipeline, Redemplo Launch Sets Commercial Trajectory
June 15, 2026
-
Arrowhead Pharmaceuticals (ARWR) Q2 2026: Redemplo Scripts Surge 40% as Cardiometabolic Pipeline Nears Data Catalyst
May 08, 2026
-
Arrowhead (ARWR) Q4 2025: $829M Partner Revenue Sets Stage for First Commercial Launch and Pipeline Acceleration
November 26, 2025
-
Arrowhead (ARWR) Q3 2025: $230M New Milestones, Four Phase III Readouts Drive Commercial Inflection
August 08, 2025
-
Arrowhead Pharmaceuticals (ARWR) Q4 2024: $825M Sarepta Deal Reshapes Pipeline and Extends Cash Runway to 2028
November 26, 2024
-
Arrowhead Pharmaceuticals (ARWR) Q3 2024: $500M Debt Facility Secured as Plazaciran Nears Commercialization
August 08, 2024
-
Arrowhead Pharmaceuticals (ARWR) Q2 2024: R&D Spend Rises 29% as Cardiometabolic Pipeline Accelerates Toward Commercialization
May 09, 2024
-
Arrowhead Pharmaceuticals (ARWR) Q1 2024: $100M Operating Burn Cut Reshapes Clinical Investment Priorities
February 06, 2024